{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T17:21:52Z","timestamp":1761153712714,"version":"3.40.4"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2012,5,22]],"date-time":"2012-05-22T00:00:00Z","timestamp":1337644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2012,5,22]],"date-time":"2012-05-22T00:00:00Z","timestamp":1337644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Infect Dis Rep"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1007\/s11908-012-0263-7","type":"journal-article","created":{"date-parts":[[2012,5,21]],"date-time":"2012-05-21T13:31:00Z","timestamp":1337607060000},"page":"381-390","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Vaccination Against Rheumatic Heart Disease: A Review of Current Research Strategies and Challenges"],"prefix":"10.1007","volume":"14","author":[{"given":"Manisha","family":"Pandey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael R.","family":"Batzloff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael F.","family":"Good","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,5,22]]},"reference":[{"key":"263_CR1","first-page":"641","volume":"84","author":"I Haffejee","year":"1992","unstructured":"Haffejee I. Rheumatic-Fever and rheumatic heart-disease - the current status of its immunology, diagnostic-criteria, and prophylaxis. Q J Med. 1992;84:641\u201358.","journal-title":"Q J Med"},{"key":"263_CR2","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1007\/s00467-002-0979-y","volume":"17","author":"A Medina","year":"2002","unstructured":"Medina A, Fernandez-Fuente M, Carbajo-Perez E, et al. Insulin-like growth factor I administration in young rats with acute renal failure. Pediatr Nephrol. 2002;17:1005\u201312.","journal-title":"Pediatr Nephrol"},{"key":"263_CR3","doi-asserted-by":"crossref","first-page":"5448","DOI":"10.4049\/jimmunol.175.8.5448","volume":"175","author":"NMJ Ellis","year":"2005","unstructured":"Ellis NMJ, Li Y, Hildebrand W, et al. T cell mimicry and epitope specificity of cross-reactive T cell clones from rheumatic heart disease. J Immunol. 2005;175:5448\u201356.","journal-title":"J Immunol"},{"key":"263_CR4","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1017\/S0950268898001952","volume":"122","author":"JR Carapetis","year":"1999","unstructured":"Carapetis JR, Walker AM, Hibble M, et al. Clinical and epidemiological features of group A streptococcal bacteraemia in a region with hyperendemic superficial streptococcal infection. Epidemiol Infect. 1999;122:59\u201365.","journal-title":"Epidemiol Infect"},{"key":"263_CR5","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/0732-8893(90)90006-H","volume":"13","author":"T Calandra","year":"1990","unstructured":"Calandra T, Glauser MP. Cytokines and septic shock. Diagn Microbiol Infect Dis. 1990;13:377\u201381.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"263_CR6","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/978-1-4899-1825-3_56","volume":"418","author":"JR Carapetis","year":"1997","unstructured":"Carapetis JR, Currie BJ. Clinical epidemiology of rheumatic fever and rheumatic heart disease in tropical Australia. Adv Exp Med Biol. 1997;418:233\u20136.","journal-title":"Adv Exp Med Biol"},{"key":"263_CR7","doi-asserted-by":"publisher","first-page":"3280","DOI":"10.1073\/pnas.91.8.3280","volume":"91","author":"DE Bessen","year":"1994","unstructured":"Bessen DE, Hollingshead SK. Allelic polymorphism of Emm loci provides evidence for horizontal gene spread in group-A streptococci. Proc Natl Acad Sci USA. 1994;91:3280\u20134.","journal-title":"Proc Natl Acad Sci USA"},{"key":"263_CR8","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1097\/00006454-199110001-00003","volume":"10","author":"M Markowitz","year":"1991","unstructured":"Markowitz M. Streptococcal disease in developing-countries. Pediatr Infect Dis J. 1991;10:S11\u20134.","journal-title":"Pediatr Infect Dis J"},{"key":"263_CR9","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1086\/506938","volume":"43","author":"MI McDonald","year":"2006","unstructured":"McDonald MI, Towers RJ, Andrews RM, et al. Low rates of streptococcal pharyngitis and high rates of pyoderma in Australian aboriginal communities where acute rheumatic fever is hyperendemic. Clin Infect Dis. 2006;43:683\u20139.","journal-title":"Clin Infect Dis"},{"key":"263_CR10","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S1473-3099(05)70267-X","volume":"5","author":"JR Carapetis","year":"2005","unstructured":"Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis. 2005;5:685\u201394.","journal-title":"Lancet Infect Dis"},{"key":"263_CR11","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S1473-3099(09)70178-1","volume":"9","author":"AC Steer","year":"2009","unstructured":"\u2022\u2022 Steer AC, Law I, Matatolu L, et al. Global emm type distribution of group A streptococci: systematic review and implications for vaccine development. Lancet Infect Dis. 2009;9:611\u20136. A study that revealed differences in the emm-type distribution of GAS across global regions and revealed difference in the epidemiology in Africa and pacific region compared to high-income countries.","journal-title":"Lancet Infect Dis"},{"key":"263_CR12","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1128\/JCM.00640-10","volume":"48","author":"S Le Hello","year":"2010","unstructured":"\u2022\u2022 Le Hello S, Doloy A, Baumann F, et al. Clinical and microbial characteristics of invasive Streptococcus pyogenes disease in New Caledonia, a region in Oceania with a high incidence of acute rheumatic fever. J Clin Microbiol. 2010;48:526\u201330 . A study conducted in New Caledonia that supported the current belief that skin infections may have a greater role pathogenesis of ARF in the tropics and prevention of pyoderma is important to limit the development of severe invasive disease.","journal-title":"J Clin Microbiol"},{"key":"263_CR13","doi-asserted-by":"crossref","unstructured":"\u2022 Steer AC, Jenney AWJ, Kado J, et al. High burden of impetigo and scabies in a tropical country. Plos Neglect Trop D 2009, 3. A comprehensive study highlighting that the impetigo and scabies disease burden are underestimated and a vaccine must be tailored to cover common types of GAS that cause impetigo.","DOI":"10.1371\/journal.pntd.0000467"},{"key":"263_CR14","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1086\/315842","volume":"182","author":"DE Bessen","year":"2000","unstructured":"Bessen DE, Carapetis JR, Beall B, et al. Contrasting molecular epidemiology of group A streptococci causing tropical and nontropical infections of the skin and throat. J Infect Dis. 2000;182:1109\u201316.","journal-title":"J Infect Dis"},{"key":"263_CR15","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1099\/jmm.0.015644-0","volume":"59","author":"PV Bramhachari","year":"2010","unstructured":"Bramhachari PV, Kaul SY, McMillan DJ, et al. Disease burden due to Streptococcus dysgalactiae subsp equisimilis (group G and C streptococcus) is higher than that due to Streptococcus pyogenes among Mumbai school children. J Med Microbiol. 2010;59:220\u20133.","journal-title":"J Med Microbiol"},{"key":"263_CR16","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/j.1440-1754.2007.01051.x","volume":"43","author":"AC Steer","year":"2007","unstructured":"Steer AC, Danchin MH, Carapetis JR. Group A streptococcal infections in children. J Paediatr Child H. 2007;43:203\u201313.","journal-title":"J Paediatr Child H"},{"key":"263_CR17","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1097\/01.qco.0000216623.82950.11","volume":"19","author":"BJ Currie","year":"2006","unstructured":"Currie BJ. Group A streptococcal infections of the skin: molecular advances but limited therapeutic progress. Curr Opin Infect Dis. 2006;19:132\u20138.","journal-title":"Curr Opin Infect Dis"},{"key":"263_CR18","first-page":"397","volume":"97","author":"RK Kumar","year":"2009","unstructured":"Kumar RK, Paul M, Francis PT. RHD in India: are we ready to shift from secondary prophylaxis to vaccinating high-risk children? Curr Sci India. 2009;97:397\u2013404.","journal-title":"Curr Sci India"},{"key":"263_CR19","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1016\/S0140-6736(02)08924-9","volume":"359","author":"EL Kaplan","year":"2002","unstructured":"Kaplan EL, Wotton JT, Johnson DR. Dynamic epidemiology of group A streptococcal serotypes. Lancet. 2002;359:2115\u20136.","journal-title":"Lancet"},{"key":"263_CR20","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1086\/444505","volume":"41","author":"AL Bisno","year":"2005","unstructured":"Bisno AL, Rubin FA, Cleary PP, Dale JB. Prospects for a group A streptococcal vaccine: rationale, feasibility, and obstacles\u2013report of a National Institute of Allergy and Infectious Diseases Workshop. Clin Infect Dis. 2005;41:1150\u20136.","journal-title":"Clin Infect Dis"},{"key":"263_CR21","first-page":"251","volume":"34","author":"AL Bloomfield","year":"1923","unstructured":"Bloomfield AL, Felty AR. Prophylactic vaccination against acute tonsillitis. Bull Johns Hopkins Hosp. 1923;34:251\u20133.","journal-title":"B Johns Hopkins Hosp"},{"key":"263_CR22","doi-asserted-by":"publisher","first-page":"0238","DOI":"10.1001\/archinte.1944.00210150041006","volume":"73","author":"LA Rantz","year":"1944","unstructured":"Rantz LA. Group A hemolytic streptococcus antibodies III. A study of the simultaneous infection of a large number of men by a single type. Arch Intern Med. 1944;73:0238\u201340.","journal-title":"Arch Intern Med"},{"key":"263_CR23","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1172\/JCI104483","volume":"41","author":"EV Potter","year":"1962","unstructured":"Potter EV, Stollerman GH, Siegel AC. Recall of type specific antibodies in man by injections of streptococcal cell walls. J Clin Invest. 1962;41:301\u201310.","journal-title":"J Clin Invest"},{"key":"263_CR24","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/infdis\/106.3.250","volume":"106","author":"WC Schmidt","year":"1960","unstructured":"Schmidt WC. Type-specific antibody formation in man following injection of streptococcal M-protein. J Infect Dis. 1960;106:250\u20135.","journal-title":"J Infect Dis"},{"key":"263_CR25","first-page":"93","volume":"54","author":"GS Medina EaC","year":"2002","unstructured":"Medina EaC GS. The potential for vaccine development against rheumatic fever. Indian Heart J. 2002;54:93\u20138.","journal-title":"Indian Heart J"},{"key":"263_CR26","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1084\/jem.124.6.1135","volume":"124","author":"EN Fox","year":"1966","unstructured":"Fox EN, Wittner MK, Dorfman A. Antigenicity of the M proteins of group A hemolytic streptococci. 3. Antibody responses and cutaneous hypersensitivity in humans. J Exp Med. 1966;124:1135\u201351.","journal-title":"J Exp Med"},{"key":"263_CR27","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1128\/am.16.3.509-518.1968","volume":"16","author":"BF Massell","year":"1968","unstructured":"Massell BF, Michael JG, Amezcua J, Siner M. Secondary and apparent primary antibody responses after group A streptococcal vaccination of 21 children. Appl Microbiol. 1968;16:509\u201318.","journal-title":"Appl Microbiol"},{"key":"263_CR28","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1093\/infdis\/131.3.217","volume":"131","author":"SM Polly","year":"1975","unstructured":"Polly SM, Waldman RH, High P, et al. Protective studies with a group-a streptococcal-M protein vaccine. 2. Challenge of volunteers after local immunization in upper respiratory-tract. J Infect Dis. 1975;131:217\u201324.","journal-title":"J Infect Dis"},{"key":"263_CR29","first-page":"108","volume":"12","author":"IM Lyampert","year":"1966","unstructured":"Lyampert IM, Danilova TA, Borodyuk NA, Beletskaya LV. Mechanism of formation of antibodies to heart tissue in immunization with group A streptococci. Folia Biol (Praha). 1966;12:108\u201315.","journal-title":"Folia Biol (Praha)"},{"key":"263_CR30","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1001\/jama.1969.03150190037007","volume":"207","author":"BF Massell","year":"1969","unstructured":"Massell BF, Honikman LH, Amezcua J. Rheumatic fever following streptococcal vaccination. Report of three cases. JAMA. 1969;207:1115\u20139.","journal-title":"JAMA"},{"key":"263_CR31","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1086\/505146","volume":"194","author":"MR Batzloff","year":"2006","unstructured":"Batzloff MR, Hartas J, Zeng WG, et al. Intranasal vaccination with a lipopeptide containing a conformationally constrained conserved minimal peptide, a universal T cell epitope, and a self-adjuvanting lipid protects mice from group A streptococcus challenge and reduces throat colonization. J Infect Dis. 2006;194:325\u201330.","journal-title":"J Infect Dis"},{"key":"263_CR32","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S0264-410X(98)00150-9","volume":"17","author":"JB Dale","year":"1999","unstructured":"Dale JB. Multivalent group A streptococcal vaccine designed to optimize the immunogenicity of six tandem M protein fragments. Vaccine. 1999;17:193\u2013200.","journal-title":"Vaccine"},{"key":"263_CR33","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1128\/IAI.70.4.2171-2177.2002","volume":"70","author":"MC Hu","year":"2002","unstructured":"Hu MC, Walls MA, Stroop SD, et al. Immunogenicity of a 26-valent group A streptococcal vaccine. Infect Immun. 2002;70:2171\u20137.","journal-title":"Infect Immun"},{"key":"263_CR34","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1086\/444458","volume":"41","author":"SA McNeil","year":"2005","unstructured":"McNeil SA, Halperin SA, Langley JM, et al. Safety and immunogenicity of 26-valent group A Streptococcus vaccine in healthy adult volunteers. Clin Infect Dis. 2005;41:1114\u201322.","journal-title":"Clin Infect Dis"},{"key":"263_CR35","first-page":"833","volume":"12","author":"JB Dale","year":"2005","unstructured":"Dale JB, Penfound T, Chiang EY, et al. Multivalent group A streptococcal vaccine elicits bactericidal antibodies against variant M subtypes. Clin Diagn Lab Immun. 2005;12:833\u20136.","journal-title":"Clin Diagn Lab Immun"},{"key":"263_CR36","doi-asserted-by":"publisher","first-page":"8175","DOI":"10.1016\/j.vaccine.2011.09.005","volume":"29","author":"JB Dale","year":"2011","unstructured":"Dale JB, Penfound TA, Chiang EY, Walton WJ. New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci. Vaccine. 2011;29:8175\u20138.","journal-title":"Vaccine"},{"key":"263_CR37","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.4049\/jimmunol.145.4.1251","volume":"145","author":"D Bessen","year":"1990","unstructured":"Bessen D, Fischetti VA. Synthetic peptide vaccine against mucosal colonization by group-a streptococci. 1. Protection against a heterologous M-serotype with shared-C repeat region epitopes. J Immunol. 1990;145:1251\u20136.","journal-title":"J Immunol"},{"key":"263_CR38","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1080\/17402520600877026","volume":"13","author":"L Guilherme","year":"2006","unstructured":"Guilherme L, Fae KC, Higa F, et al. Towards a vaccine against rheumatic fever. Clin Dev Immunol. 2006;13:125\u201332.","journal-title":"Clin Dev Immunol"},{"key":"263_CR39","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.ymeth.2009.03.024","volume":"49","author":"L Guilherme","year":"2009","unstructured":"Guilherme L, Postol E, de Barros SF, et al. A vaccine against S. pyogenes: design and experimental immune response. Methods. 2009;49:316\u201321.","journal-title":"Methods"},{"key":"263_CR40","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1086\/374800","volume":"187","author":"MR Batzloff","year":"2003","unstructured":"Batzloff MR, Hayman WA, Davies MR, et al. Protection against group A streptococcus by immunization with J8-diphtheria toxoid: contribution of J8- and diphtheria toxoid-specific antibodies to protection. J Infect Dis. 2003;187:1598\u2013608.","journal-title":"J Infect Dis"},{"key":"263_CR41","doi-asserted-by":"crossref","unstructured":"\u2022 Pandey M, Batzloff MR, Good MF. Mechanism of protection induced by group A streptococcus vaccine candidate J8-DT: contribution of B and T-cells towards protection. Plos One 2009;4:Article No.: e5147. A study that utilised conserved region vaccine J8-DT and demonstrated the role of antibodies in protection.","DOI":"10.1371\/journal.pone.0005147"},{"key":"263_CR42","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1128\/IAI.70.5.2734-2738.2002","volume":"70","author":"C Olive","year":"2002","unstructured":"Olive C, Batzloff MR, Horvath A, et al. A lipid core peptide construct containing a conserved region determinant of the group A streptococcal M protein elicits heterologous opsonic antibodies. Infect Immun. 2002;70:2734\u20138.","journal-title":"Infect Immun"},{"key":"263_CR43","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1016\/S0264-410X(02)00205-0","volume":"20","author":"C Olive","year":"2002","unstructured":"Olive C, Clair T, Yarwood P, Good MR. Protection of mice from group A streptococcal infection by intranasal immunisation with a peptide vaccine that contains a conserved M protein B cell epitope and lacks a T cell autoepitope. Vaccine. 2002;20:2816\u201325.","journal-title":"Vaccine"},{"key":"263_CR44","first-page":"88","volume":"119","author":"C Olive","year":"2004","unstructured":"Olive C, Batzloff M, Horvath A, et al. Group A streptococcal vaccine delivery by immunization with a self-adjuvanting M protein-based lipid core peptide construct. Indian J Med Res. 2004;119:88\u201394.","journal-title":"Indian J Med Res"},{"key":"263_CR45","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1002\/prca.200780048","volume":"2","author":"JN Cole","year":"2008","unstructured":"Cole JN, Henningham A, Gillen CM, et al. Human pathogenic streptococcal proteomics and vaccine development. Proteonomics Clin Appl. 2008;2:387\u2013410.","journal-title":"Proteonomics Clin Appl"},{"key":"263_CR46","doi-asserted-by":"publisher","first-page":"7342","DOI":"10.1128\/IAI.72.12.7342-7345.2004","volume":"72","author":"J McArthur","year":"2004","unstructured":"McArthur J, Medina E, Mueller A, et al. Intranasal vaccination with streptococcal fibronectin binding protein Sfb1 fails to prevent growth and dissemination of Streptococcus pyogenes in a murine skin infection model. Infect Immun. 2004;72:7342\u20135.","journal-title":"Infect Immun"},{"key":"263_CR47","doi-asserted-by":"publisher","first-page":"6088","DOI":"10.1016\/j.vaccine.2006.05.024","volume":"24","author":"K Schulze","year":"2006","unstructured":"Schulze K, Olive C, Ebensen T, Guzman CA. Intranasal vaccination with SfbI or M protein-derived peptides conjugated to diphtheria toxoid confers protective immunity against a lethal challenge with Streptococcus pyogenes. Vaccine. 2006;24:6088\u201395.","journal-title":"Vaccine"},{"key":"263_CR48","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1128\/IAI.69.2.924-930.2001","volume":"69","author":"S Kawabata","year":"2001","unstructured":"Kawabata S, Kunitomo E, Terao Y, et al. Systemic and mucosal immunizations with fibronectin-binding protein FBP54 induce protective immune responses against Streptococcus pyogenes challenge in mice. Infect Immun. 2001;69:924\u201330.","journal-title":"Infect Immun"},{"key":"263_CR49","doi-asserted-by":"publisher","first-page":"4332","DOI":"10.1016\/j.vaccine.2004.04.030","volume":"22","author":"PP Cleary","year":"2004","unstructured":"Cleary PP, Matsuka YV, Huynh T, et al. Immunization with C5a peptidase from either group A or B streptococci enhances clearance of group A streptococci from intranasally infected mice. Vaccine. 2004;22:4332\u201341.","journal-title":"Vaccine"},{"key":"263_CR50","doi-asserted-by":"publisher","first-page":"7878","DOI":"10.1128\/IAI.73.12.7878-7886.2005","volume":"73","author":"HS Park","year":"2005","unstructured":"Park HS, Cleary PP. Active and passive intranasal immunizations with streptococcal surface protein c5a peptidase prevent infection of murine nasal mucosa-associated lymphoid tissue, a functional homologue of human tonsils. Infect Immun. 2005;73:7878\u201386.","journal-title":"Infect Immun"},{"key":"263_CR51","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1128\/iai.65.6.2080-2087.1997","volume":"65","author":"YD Ji","year":"1997","unstructured":"Ji YD, Carlson B, Kondagunta A, Cleary PP. Intranasal immunization with C5a peptidase prevents nasopharyngeal colonization of mice by the group A Streptococcus. Infect Immun. 1997;65:2080\u20137.","journal-title":"Infect Immun"},{"key":"263_CR52","first-page":"95","volume":"119","author":"A Shet","year":"2004","unstructured":"Shet A, Kaplan E, Johnson D, Cleary PP. Human immunogenicity studies on group A streptococcal C5a peptidase (SCPA) as a potential vaccine against group A streptococcal infections. Indian J Med Res. 2004;119:95\u20138.","journal-title":"Indian J Med Res"},{"key":"263_CR53","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1128\/iai.64.7.2387-2390.1996","volume":"64","author":"I Chmouryguina","year":"1996","unstructured":"Chmouryguina I, Suvorov A, Ferrieri P, Cleary PP. Conservation of the C5a peptidase genes in group A and B streptococci. Infect Immun. 1996;64:2387\u201390.","journal-title":"Infect Immun"},{"key":"263_CR54","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1084\/jem.48.6.769","volume":"48","author":"RC Lancefield","year":"1928","unstructured":"Lancefield RC, Todd EW. Antigenic differences between matt hemolytic streptococci and their glossy variants. J Exp Med. 1928;48:769\u201390.","journal-title":"J Exp Med"},{"key":"263_CR55","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1093\/infdis\/171.3.593","volume":"171","author":"LG Salvadori","year":"1995","unstructured":"Salvadori LG, Blake MS, Mccarty M, et al. Group-A streptococcus-liposome ELISA antibody-titers to group-A polysaccharide and opsonophagocytic capabilities of the antibodies. J Infect Dis. 1995;171:593\u2013600.","journal-title":"J Infect Dis"},{"key":"263_CR56","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/978-1-4899-1825-3_214","volume":"418","author":"JB Zabriskie","year":"1997","unstructured":"Zabriskie JB, Poon-King T, Blake MS, et al. Phagocytic, serological, and protective properties of streptococcal group A carbohydrate antibodies. Adv Exp Med Biol. 1997;418:917\u20139.","journal-title":"Adv Exp Med Biol"},{"key":"263_CR57","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1016\/j.vaccine.2005.06.039","volume":"24","author":"K Schulze","year":"2006","unstructured":"Schulze K, Medina E, Guzman CA. Intranasal immunization with serum opacity factor (SOF) of Streptococcus pyogenes fails to protect mice against lethal mucosal challenge with a heterologous strain. Vaccine. 2006;24:1446\u201350.","journal-title":"Vaccine"},{"key":"263_CR58","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1084\/jem.189.1.89","volume":"189","author":"T Proft","year":"1999","unstructured":"Proft T, Moffatt SL, Berkahn CJ, Fraser JD. Identification and characterization of novel superantigens from Streptococcus pyogenes. J Exp Med. 1999;189:89\u2013101.","journal-title":"J Exp Med"},{"key":"263_CR59","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/S1473-3099(02)00222-0","volume":"2","author":"M Llewelyn","year":"2002","unstructured":"Llewelyn M, Cohen J. Superantigens: microbial agents that corrupt immunity. Lancet Infect Dis. 2002;2:156\u201362.","journal-title":"Lancet Infect Dis"},{"key":"263_CR60","doi-asserted-by":"crossref","unstructured":"Ulrich R. Vaccine based on a ubiquitous cysteinyl protease and streptococcal pyrogenic exotoxin A protects against streptococcus pyogenes sepsis and toxic shock. J Immune based Ther Vaccines 2008;6.","DOI":"10.1186\/1476-8518-6-8"},{"key":"263_CR61","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/S0020-7519(01)00360-5","volume":"32","author":"MF Good","year":"2002","unstructured":"Good MF, Xu H, Batzloff M. Adapting immunity with subunit vaccines: case studies with group A Streptococcus and malaria. Int J Parasitol. 2002;32:575\u201380.","journal-title":"Int J Parasitol"},{"key":"263_CR62","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1046\/j.1365-2567.1997.00365.x","volume":"92","author":"M Kreutz","year":"1997","unstructured":"Kreutz M, Ackermann U, Hauschildt S, et al. A comparative analysis of cytokine production and tolerance induction by bacterial lipopeptides, lipopolysaccharides and staphyloccocus aureus in human monocytes. Immunology. 1997;92:396\u2013401.","journal-title":"Immunology"},{"key":"263_CR63","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1084\/jem.142.2.473","volume":"142","author":"F Melchers","year":"1975","unstructured":"Melchers F, Braun V, Galanos C. The lipoprotein of the outer membrane of Escherichia coli: a B-lymphocyte mitogen. J Exp Med. 1975;142:473\u201382.","journal-title":"J Exp Med"},{"key":"263_CR64","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1046\/j.1462-5822.2000.00050.x","volume":"2","author":"CD Ashbaugh","year":"2000","unstructured":"Ashbaugh CD, Moser TJ, Shearer MH, et al. Bacterial determinants of persistent throat colonization and the associated immune response in a primate model of human group A streptococcal pharyngeal infection. Cell Microbiol. 2000;2:283\u201392.","journal-title":"Cell Microbiol"},{"key":"263_CR65","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1046\/j.1365-2958.2001.02635.x","volume":"42","author":"L Gryllos","year":"2001","unstructured":"Gryllos L, Cywes C, Shearer MH, et al. Regulation of capsule gene expression by group A Streptococcus during pharyngeal colonization and invasive infection. Mol Microbiol. 2001;42:61\u201374.","journal-title":"Mol Microbiol"},{"key":"263_CR66","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1086\/466528","volume":"192","author":"MR Batzloff","year":"2005","unstructured":"Batzloff MR, Yan H, Davies MR, et al. Toward the development of an antidisease, transmission-blocking intranasal vaccine for group a streptococcus. J Infect Dis. 2005;192:1450\u20135.","journal-title":"J Infect Dis"},{"key":"263_CR67","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1046\/j.1365-2567.2002.01396.x","volume":"106","author":"L BenMohamed","year":"2002","unstructured":"BenMohamed L, Krishnan R, Auge C, et al. Intranasal administration of a synthetic lipopeptide without adjuvant induces systemic immune responses. Immunology. 2002;106:113\u201321.","journal-title":"Immunology"},{"key":"263_CR68","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.4049\/jimmunol.171.5.2532","volume":"171","author":"HS Park","year":"2003","unstructured":"Park HS, Francis KP, Yu J, Cleary PP. Membranous cells in nasal-associated lymphoid tissue: A portal of entry for the respiratory mucosal pathogen group A streptococcus. J Immunol. 2003;171:2532\u20137.","journal-title":"J Immunol"},{"key":"263_CR69","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.micpath.2006.01.005","volume":"40","author":"TL Dalton","year":"2006","unstructured":"Dalton TL, Hobb RI, Scott JR. Analysis of the role of CovR and CovS in the dissemination of Streptococcus pyogenes in invasive skin disease. Microb Pathog. 2006;40:221\u20137.","journal-title":"Microb Pathog"},{"key":"263_CR70","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.micpath.2008.05.009","volume":"45","author":"F Luo","year":"2008","unstructured":"Luo F, Lizano S, Banik S, et al. Role of Mga in group A streptococcal infection at the skin epithelium. Microb Pathog. 2008;45:217\u201324.","journal-title":"Microb Pathog"},{"key":"263_CR71","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1128\/IAI.66.8.3931-3935.1998","volume":"66","author":"CF Kuo","year":"1998","unstructured":"Kuo CF, Wu JJ, Lin KY, et al. Role of streptococcal pyrogenic exotoxin B in the mouse model of group A streptococcal infection. Infect Immun. 1998;66:3931\u20135.","journal-title":"Infect Immun"},{"key":"263_CR72","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1086\/515241","volume":"177","author":"MDP Boyle","year":"1998","unstructured":"Boyle MDP, Raeder R, Flosdorff A, Podbielski A. Role of emm and mrp genes in the virulence of group A streptococcal isolate 64\/14 in a mouse model of skin infection. J Infect Dis. 1998;177:991\u20137.","journal-title":"J Infect Dis"},{"key":"263_CR73","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.1128\/iai.65.12.4926-4930.1997","volume":"65","author":"AL Bisno","year":"1997","unstructured":"Bisno AL, Gaviria JM. Murine model of recurrent group G streptococcal cellulitis: No evidence of protective immunity. Infect Immun. 1997;65:4926\u201330.","journal-title":"Infect Immun"},{"key":"263_CR74","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1172\/JCI3065","volume":"102","author":"CD Ashbaugh","year":"1998","unstructured":"Ashbaugh CD, Warren HB, Carey VJ, Wessels MR. Molecular analysis of the role of the group A streptococcal cysteine protease, hyaluronic acid capsule, and M protein in a murine model of human invasive soft-tissue infection. J Clin Invest. 1998;102:550\u201360.","journal-title":"J Clin Invest"},{"key":"263_CR75","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.1128\/iai.61.9.3696-3702.1993","volume":"61","author":"R Raeder","year":"1993","unstructured":"Raeder R, Boyle MDP. Association of type-Ii immunoglobulin-G-binding protein expression and survival of group-A streptococci in human blood. Infect Immun. 1993;61:3696\u2013702.","journal-title":"Infect Immun"},{"key":"263_CR76","doi-asserted-by":"publisher","first-page":"2880","DOI":"10.1128\/IAI.68.5.2880-2887.2000","volume":"68","author":"DA Scaramuzzino","year":"2000","unstructured":"Scaramuzzino DA, McNiff JM, Bessen DE. Humanized in vivo model for streptococcal impetigo. Infect Immun. 2000;68:2880\u20137.","journal-title":"Infect Immun"},{"key":"263_CR77","doi-asserted-by":"publisher","first-page":"4072","DOI":"10.1128\/IAI.69.6.4072-4078.2001","volume":"69","author":"A Quinn","year":"2001","unstructured":"Quinn A, Kosanke S, Fischetti VA, et al. Induction of autoimmune valvular heart disease by recombinant streptococcal M protein. Infect Immun. 2001;69:4072\u20138.","journal-title":"Infect Immun"},{"key":"263_CR78","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1172\/JCI5118","volume":"103","author":"JB Dale","year":"1999","unstructured":"Dale JB, Chiang EY, Liu S, et al. New protective antigen of group A streptococci. J Clin Invest. 1999;103:1261\u20138.","journal-title":"J Clin Invest"},{"key":"263_CR79","doi-asserted-by":"crossref","first-page":"4418","DOI":"10.1128\/IAI.66.9.4418-4424.1998","volume":"66","author":"A Quinn","year":"1998","unstructured":"Quinn A, Ward K, Fischetti VA, et al. Immunological relationship between the class I epitope of streptococcal M protein and myosin. Infect Immun. 1998;66:4418\u201324.","journal-title":"Infect Immun"},{"key":"263_CR80","doi-asserted-by":"publisher","first-page":"5714","DOI":"10.1073\/pnas.85.15.5714","volume":"85","author":"DE Hruby","year":"1988","unstructured":"Hruby DE, Hodges WM, Wilson EM, et al. Expression of streptococcal M-protein in mammalian-cells. Proc Natl Acad Sci USA. 1988;85:5714\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"263_CR81","doi-asserted-by":"crossref","first-page":"A26","DOI":"10.1172\/JCI105712","volume":"47","author":"BA Dudding","year":"1968","unstructured":"Dudding BA, Ayoub EM. Persistence of Group a Streptococcal carbohydrate antibodies in patients with chronic inactive rheumatic heart disease. J Clin Invest. 1968;47:A26-&.","journal-title":"J Clin Invest"},{"key":"263_CR82","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.4049\/jimmunol.141.8.2760","volume":"141","author":"MW Cunningham","year":"1988","unstructured":"Cunningham MW, McCormack JM, Talaber LR, et al. Human monoclonal antibodies reactive with antigens of the group A Streptococcus and human heart. J Immunol. 1988;141:2760\u20136.","journal-title":"J Immunol"},{"key":"263_CR83","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1006\/mpat.1994.1044","volume":"16","author":"V Kapur","year":"1994","unstructured":"Kapur V, Maffei JT, Greer RS, et al. Vaccination with streptococcal extracellular cysteine protease (Interleukin-1-Beta Convertase) protects mice against challenge with heterologous group-A streptococci. Microb Pathog. 1994;16:443\u201350.","journal-title":"Microb Pathog"},{"key":"263_CR84","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1006\/mpat.1994.1057","volume":"17","author":"P Valentinweigand","year":"1994","unstructured":"Valentinweigand P, Talay SR, Kaufhold A, et al. The fibronectin-binding domain of the Sfb protein adhesin of Streptococcus-Pyogenes occurs in many group-A streptococci and does not cross-react with heart myosin. Microb Pathog. 1994;17:111\u201320.","journal-title":"Microb Pathog"}],"container-title":["Current Infectious Disease Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11908-012-0263-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11908-012-0263-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11908-012-0263-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11908-012-0263-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T03:19:20Z","timestamp":1744168760000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11908-012-0263-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,22]]},"references-count":84,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["263"],"URL":"https:\/\/doi.org\/10.1007\/s11908-012-0263-7","relation":{},"ISSN":["1523-3847","1534-3146"],"issn-type":[{"type":"print","value":"1523-3847"},{"type":"electronic","value":"1534-3146"}],"subject":[],"published":{"date-parts":[[2012,5,22]]},"assertion":[{"value":"22 May 2012","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}